New combo aims to supercharge immune system against pancreatic cancer
NCT ID NCT03727880
First seen Feb 04, 2026 · Last updated May 24, 2026 · Updated 14 times
Summary
This study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy could help the immune system fight pancreatic cancer before and after surgery. Twenty-eight adults with early-stage, removable pancreatic cancer participated. The goal was to see if this combination could destroy more cancer cells and delay recurrence, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Samuel Oschin Cancer Center at Cedars-Sinai
Los Angeles, California, 90048, United States
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
The University of Texas Health Science Center San Antonio
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.